Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Leiomyoma

Myofibroma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasms, Connective Tissue

Connective Tissue Diseases

Reproductive Control Agents

All Drugs and Chemicals

Mifepristone

Contraceptive Agents

Contraceptives, Oral

Contraceptive Agents, Female

Contraceptives, Postcoital

Hormones

Hormone Antagonists

Contraceptive Agents, Hormonal

Mifepristone (Mifegyne) 50 mg every other day for 3 months

Mifegyne

placebo

Kristina Gemzell Danielsson, Prof.MD.PHD

Uterine fibroids are a benign but common condition among women in reproductive age. It is one of the most common reasons for hysterectomy since it often causes bleeding problems sometimes leading to anemia. Several alternative treatment regimens have been investigated that could replace surgery. The antiprogesterone, mifepristone, is one of the most promising drugs that have been tested. In addition to the inhibiting effect on the growth of uterine fibroids antiprogestins have been proposed to have an antiproliferative effect on breast tissue.

The purpose of the present study is to evaluate the effect of mifepristone on the volume of uterine fibroids. The study will also address the effect of mifepristone on the breast tissue

Other purposes of this study include:

* To develop a new non-surgical method for treatment of uterine fibroids
* To study the effect of mifepristone on the size of uterine fibroids
* To evaluate factors regulating fibroid growth by comparison with untreated fibroids and normal myometrium
* To study the effect of mifepristone on the amount of blood loss and pelvic pain in patients with fibroids
* To study the effect of mifepristone on proliferation of breast tissue

The Effect of Mifepristone on Uterine Fibroids and Breast Tissue

The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue

Karolinska Institutet

Kristina Gemzell Danielsson, Professor, MD,PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue	NCT00579475	Uterine Fibroid...	Mifegyne placebo	18 Years -	Karolinska Institutet
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue	NCT00579475	Uterine Fibroid...	Mifegyne placebo	18 Years -	Karolinska Institutet

Spots Global Cancer Trial Database for breast epithelial cell proliferation